Append Medical

Append Medical is at the forefront of innovation in the medical device industry, addressing a critical need for safer and more effective stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Millions worldwide suffer from NVAF, which significantly increases the risk of stroke, often due to blood clots originating in the left atrial appendage (LAA) of the heart. Traditional LAA occlusion solutions typically involve implanting a device in the heart, which can introduce risks such as device-related thromboembolism (DRT) and peri-device leakage (PDL), both of which can paradoxically increase the likelihood of stroke. Append Medical’s proprietary transcatheter system eliminates the need for any implantable device. Instead, it uses a sophisticated vacuum mechanism to invert and ligate the LAA tissue, effectively sealing it off without leaving foreign material inside the heart. This approach not only mitigates the inherent risks associated with current implant-based solutions but also allows the system to be universally adaptable to a wide range of patient anatomies. The procedure is designed to be fast, minimally invasive, and highly effective, promising to disrupt the LAA occlusion market and set a new standard in stroke prevention. With a leadership team and advisory board comprising leading cardiologists and cardiac surgeons from renowned institutions, Append Medical is positioned to make a significant impact on cardiovascular care and patient outcomes, contributing to the global effort to reduce the burden of stroke and improve quality of life for those with atrial fibrillation